Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy

Psycho-emotional disorders such as depression and anxiety disorders are important modifiable risk factors for the development and complicated course of many common chronic non-communicable diseases. A particular feature of such comorbidity is the significant impact of psycho-emotional disorders on t...

Full description

Bibliographic Details
Main Authors: V. N. Shishkova, В. Н. Шишкова
Format: Article in Journal/Newspaper
Language:Russian
Published: REMEDIUM GROUP Ltd. 2023
Subjects:
буспирон
depression
anxiety disorders
chronic non-communicable diseases
comorbidity
tofisopam
buspirone
депрессия
тревожные расстройства
хронические неинфекционные заболевания
коморбидность
тофизопам
Arctic
Online Access:https://www.med-sovet.pro/jour/article/view/7734
https://doi.org/10.21518/ms2023-230
id ftjmedsovet:oai:oai.medsovet.elpub.ru:article/7734
record_format openpolar
institution Open Polar
collection Medical Council (E-Journal)
op_collection_id ftjmedsovet
language Russian
topic буспирон
depression
anxiety disorders
chronic non-communicable diseases
comorbidity
tofisopam
buspirone
депрессия
тревожные расстройства
хронические неинфекционные заболевания
коморбидность
тофизопам
spellingShingle буспирон
depression
anxiety disorders
chronic non-communicable diseases
comorbidity
tofisopam
buspirone
депрессия
тревожные расстройства
хронические неинфекционные заболевания
коморбидность
тофизопам
V. N. Shishkova
В. Н. Шишкова
Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy
topic_facet буспирон
depression
anxiety disorders
chronic non-communicable diseases
comorbidity
tofisopam
buspirone
депрессия
тревожные расстройства
хронические неинфекционные заболевания
коморбидность
тофизопам
description Psycho-emotional disorders such as depression and anxiety disorders are important modifiable risk factors for the development and complicated course of many common chronic non-communicable diseases. A particular feature of such comorbidity is the significant impact of psycho-emotional disorders on the motivation and adherence of patients to a healthy lifestyle and various therapy options, which increases the risks of complications and, as a consequence of this, the healthcare expenditures. The topicality of the issues of screening and management of psycho-emotional disorders in the general practitioner practice is caused, on the one hand, by high rate of these disorders in patients with chronic non-communicable diseases, deterioration in quality of life and an increase in adverse outcomes, and on the other hand, inadequate awareness of the possibilities to manage the psycho-emotional state of patients with comorbidities. The therapy for psycho-emotional disorders includes both drug and non-drug methods, however, the effectiveness of such therapy in relation to the clinical course and prognosis in patients with different comorbidities is not the same. This review presents the most common comorbidities of psycho-emotional disorders and somatic diseases in therapeutic practice. A buspirone and tofisopam therapy for psycho-emotional disorders in patients with various comorbidities was discussed. The efficacy and safety of tofisopam and buspirone have been studied in numerous studies in patients with chronic diseases and a wide range of anxiety disorders, including a long-term administration. Психоэмоциональные нарушения, такие как депрессия и тревожные расстройства, являются важными модифицируемыми факторами риска развития и осложненного течения многих распространенных хронических неинфекционных заболеваний. Особенностью данной коморбидности является значимое влияние психоэмоциональных расстройств на мотивацию и приверженность пациентов к здоровому образу жизни и различным вариантам терапии, увеличивая риски ...
format Article in Journal/Newspaper
author V. N. Shishkova
В. Н. Шишкова
author_facet V. N. Shishkova
В. Н. Шишкова
author_sort V. N. Shishkova
title Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy
title_short Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy
title_full Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy
title_fullStr Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy
title_full_unstemmed Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy
title_sort psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy
publisher REMEDIUM GROUP Ltd.
publishDate 2023
url https://www.med-sovet.pro/jour/article/view/7734
https://doi.org/10.21518/ms2023-230
genre Arctic
genre_facet Arctic
op_source Meditsinskiy sovet = Medical Council; № 13 (2023); 256-262
Медицинский Совет; № 13 (2023); 256-262
2658-5790
2079-701X
op_relation https://www.med-sovet.pro/jour/article/view/7734/6871
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/s01406736(18)32279-7.
Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В., Александрова Л.М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. https://doi.org/10.15829/1728-8800-2022-3235.
Драпкина О.М., Шишкова В.Н., Котова М.Б. Психоэмоциональные факторы риска хронических неинфекционных заболеваний в амбулаторной практике. Методические рекомендации для терапевтов. Кардио васкулярная терапия и профилактика. 2022;21(10):3438. https://doi.org/10.15829/1728-8800-2022-3438.
Шишкова В.Н., Драницына Б.Г., Драпкина О.М. Алгоритмы ведения пациентов с тревогой в практике терапевта. Кардиоваскулярная терапия и профилактика. 2023;22(2):3526. https://doi.org/10.15829/1728-88002023-3526.
Tong A., Wang X., Li F., Xu F., Li Q., Zhang F. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: a meta-analysis of prospective cohort studies. Acta Diabetol. 2016;53(4):589–598. https://doi.org/10.1007/s00592-016-0845-1.
Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–191. https://doi.org/10.1038/ki.2013.77.
Xiao T., Qiu H., Chen Y., Zhou X., Wu K., Ruan X., Wang N., Fu C. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 2018;18(1):89. https://doi.org/10.1186/s12888-018-1671-5.
Krebber A.M., Buffart L.M., Kleijn G., Riepma I.C., de Bree R., Leemans C.R. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130. https://doi.org/10.1002/pon.3409.
Read J.R., Sharpe L., Modini M., Dear B.F. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017;221:36–46. https://doi.org/10.1016/j.jad.2017.06.009.
Ronaldson A., Arias de la Torre J., Prina M., Armstrong D., Das-Munshi J., Hatch S. et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. Lancet Reg Health Eur. 2021;8:100149. https://doi.org/10.1016/j.lanepe.2021.100149.
Long J., Ouyang Y., Duan H., Xiang Z., Ma H., Ju M., Sun D. Multiple Factor Analysis of Depression and/or Anxiety in Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1449–1464. https://doi.org/10.2147/COPD.S245842.
Wen-Tao D., Xue-Xiu C., Zun-Jiang C., Wei C., Cheng-Feng P., Xing-Ken F. The Relationship Between Hospitalization Frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Anxiety and Depression. Front Genet. 2022;13:817727. https://doi.org/10.3389/fgene.2022.817727.
Volpato E., Toniolo S., Pagnini F., Banfi P. The Relationship Between Anxiety, Depression and Treatment Adherence in Chronic Obstructive Pulmonary Disease: A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2021;16:2001–2021. https://doi.org/10.2147/COPD.S313841.
Ställberg B., Janson C., Larsson K., Johansson G., Kostikas K., Gruenberger J.B. et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. https://doi.org/10.1038/s41533-018-0101-y.
Zareifopoulos N., Bellou A., Spiropoulou A., Spiropoulos K. Prevalence, Contribution to Disease Burden and Management of Comorbid Depression and Anxiety in Chronic Obstructive Pulmonary Disease: A Narrative Review. COPD. 2019;16(5-6):406–417. https://doi.org/10.1080/15412555.2019.1679102.
Peyrot M., Rubin R.R., Lauritzen T., Snoek F.J., Matthews D.R., Skovlund S.E. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379–1385. https://doi.org/10.1111/j.1464-5491.2005.01644.x.
Perrin N.E., Davies M.J., Robertson N., Snoek F.J., Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34(11):1508–1520. https://doi.org/10.1111/dme.13448.
Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383–2390. https://doi.org/10.2337/dc08-0985.
Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med. 2006;23(4):445–448. https://doi.org/10.1111/j.1464-5491.2006.01814.x.
Huang C.J., Hsieh H.M., Tu H.P., Jiang H.J., Wang P.W., Lin C.H. Generalized anxiety disorder in type 2 diabetes mellitus: prevalence and clinical characteristics. Braz J Psychiatry. 2020;42(6):621–629. https://doi.org/10.1590/1516-4446-2019-0605.
Deschênes S.S., Burns R.J., Schmitz N. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: findings from the 2012 Canadian Community Health Survey – Mental Health (CCHS-MH). J Psychosom Res. 2015;78(2):137–142. https://doi.org/10.1016/j.jpsychores.2014.11.023.
Ásbjörnsdóttir B., Vestgaard M., Do N.C., Ringholm L., Andersen L.L.T., Jensen D.M. et al. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Diabet Med. 2021;38(3):e14506. https://doi.org/10.1111/dme.14506.
Van der Feltz-Cornelis C., Allen S.F., Holt R.I.G., Roberts R., Nouwen A., Sartorius N. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav. 2021;11(2):e01981. https://doi.org/10.1002/brb3.1981.
Winkley K., Upsher R., Stahl D., Pollard D., Kasera A., Brennan A. et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24(28):1–232. https://doi.org/10.3310/hta24280.
Stasiak C.E., Bazan K.S., Kuss R.S., Schuinski A.F., Baroni G. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014;36(3):325–331. https://doi.org/10.5935/0101-2800.20140047.
Nagler E.V., Webster A.C., Vanholder R., Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736–3745. https://doi.org/10.1093/ndt/gfs295.
Chilcot J., Farrington K. The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease. J Am Soc Nephrol. 2019;30(7):1339–1340. https://doi.org/10.1681/ASN.2019030308.
Wasteson E. Mood disorders in patients with cancer. Lancet Oncol. 2011;12(2):114–115. https://doi.org/10.1016/S1470-2045(11)70007-9.
Wang Y.H., Li J.Q., Shi J.F., Que J.Y., Liu J.J., Lappin J.M. et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487–1499. https://doi.org/10.1038/s41380-019-0595-x.
Celano C.M., Millstein R.A., Bedoya C.A., Healy B.C., Roest A.M., Huffman J.C. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105–1115. https://doi.org/10.1016/j.ahj.2015.09.013.
Шишкова В.Н., Устарбекова Д.Б., Шишков В.А., Имамгаязова К.Э., Капустина Л.А. Психоэмоциональные нарушения у пациентов с хронической сердечной недостаточностью. Терапия. 2022;(1):44–49. https://doi.org/10.18565/therapy.2022.1.44-49.
Шишкова В.Н. Простые и эффективные решения в коррекции тревоги и стресса. Медицинский совет. 2023;(3):161–167. https://doi.org/10.21518/ms2023-023.
Vaccarino V., Badimon L., Bremner J.D, Cenko E., Cubedo J., Dorobantu M. et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687–1696. https://doi.org/10.1093/eurheartj/ehy913.
Daskalopoulou M., George J., Walters K., Osborn D.P., Batty G.D., Stogiannis D. et al. Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1.9 Million Women and Men. PLoS ONE. 2016;11(4):e0153838. https://doi.org/10.1371/journal.pone.0153838.
Peters A., McEwen B.S. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015;56:139–150. https://doi.org/10.1016/j.neubiorev.2015.07.001.
Albus C., Waller C., Fritzsche K., Gunold H., Haass M., Hamann B. et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175–1196. https://doi.org/10.1007/s00392-019-01488-w.
Smyth A., O’Donnell M., Lamelas P., Teo K., Rangarajan S., Yusuf S. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. Circulation. 2016;134(15):1059–1067. https://doi.org/10.1161/CIRCULATIONAHA.116.023142.
Евстифеева С.Е., Шальнова С.А., Макарова Ю.К., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. и др. Ассоциируется ли уровень тревоги и депрессии в популяции со смертностью населения? По данным исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2021;20(5):3009. https://doi.org/10.15829/1728-8800-2021-3009.
Moise N., Khodneva Y., Jannat-Khah D.P., Richman J., Davidson K.W., Kronish I.M. et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385. https://doi.org/10.1136/bmjopen-2017-017385.
Ye S., Muntner P., Shimbo D., Judd S.E., Richman J., Davidson K.W., Safford M.M. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: the REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013;61(6):622–630. https://doi.org/10.1016/j.jacc.2012.09.058.
Tully P.J., Cosh S.M., Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77(6):439–448. https://doi.org/10.1016/j.jpsychores.2014.10.001.
Thompson D.R., Ski C.F. Psychosocial interventions in cardiovascular disease – what are they? Eur J Prev Cardiol. 2013;20(6):916–917. https://doi.org/10.1177/2047487313494031.
Pizzi C., Rutjes A.W., Costa G.M., Fontana F., Mezzetti A., Manzoli L. Metaanalysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972–979. https://doi.org/10.1016/j.amjcard.2010.11.017.
He W., Zhou Y., Ma J., Wei B., Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(6):919–926. https://doi.org/10.1007/s10741-019-09850-w.
Honkola J., Hookana E., Malinen S., Kaikkonen K.S., Junttila M.J., Isohanni M. et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33(6):745–751. https://doi.org/10.1093/eurheartj/ehr368.
Шишкова В.Н. Стратегия ведения и профилактики психоэмоциональных нарушений в практике терапевта. Медицинский совет. 2023;(6):76–82. https://doi.org/10.21518/ms2023-077.
Стаценко М.Е., Говоруха О.А. Влияние Грандаксина на показатели качества жизни и темп реабилитации больных с сердечной недостаточностью, перенесших инфаркт миокарда. Лекарственный вестник. 2004;(2):23–28. Режим доступа: http://attic.volgmed.ru/publishing/lv/s/2004/2/lv-2004-2–023.pdf.
Кулешова Э.В. Применение тофизопама (грандаксина) для лечения больных ишемической болезнью сердца. Клиническая фармакология и терапия. 2000;9(5):53–55. Режим доступа: https://medi.ru/info/8089/.
Левин О.С. Применение буспирона в клинической практике. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(4):83–87. https://doi.org/10.17116/jnevro20151154183-87.
op_rights Authors publishing their articles in this journal shall agree to the following:Authors reserve the copyright to the work and grant the journal a license to publish the work for the first time Creative Commons Attribution License (CC BY- NC-ND), which allows other persons to distribute this work with the obligatory preservation of references to the authors of the original work and the original publication in this journal.Authors reserve the right to conclude separate contractual arrangements regarding the non-exclusive distribution of the work version in the form published here (for example, posting it in the institute’s repository, publication in a book), with reference to its original publication in this journal.Authors have the right to post work on the Internet (for example, in the institute’s repository or personal website) before and during the process of considering it by this journal, as this can result in a productive discussion and more references to this work.
Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License (CC BY- NC-ND), которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию.Авторы имеют право размещать работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу. (См. The Effect of Open Access).
op_doi https://doi.org/10.21518/ms2023-23010.1016/s01406736(18)32279-710.15829/1728-8800-2022-323510.15829/1728-8800-2022-343810.15829/1728-88002023-352610.1007/s00592-016-0845-110.1038/ki.2013.7710.1186/s12888-018-1671-510.1002/pon.340910.1016/j.jad.2017.06.009
_version_ 1778133249080426496
spelling ftjmedsovet:oai:oai.medsovet.elpub.ru:article/7734 2023-09-26T15:12:42+02:00 Psycho-emotional state of patients with chronic non-communicable diseases: important aspects of therapy Психоэмоциональное состояние пациентов с хроническими неинфекционными заболеваниями: важные аспекты терапии V. N. Shishkova В. Н. Шишкова 2023-08-20 application/pdf https://www.med-sovet.pro/jour/article/view/7734 https://doi.org/10.21518/ms2023-230 rus rus REMEDIUM GROUP Ltd. https://www.med-sovet.pro/jour/article/view/7734/6871 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/s01406736(18)32279-7. Драпкина О.М., Концевая А.В., Калинина А.М., Авдеев С.Н., Агальцов М.В., Александрова Л.М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. https://doi.org/10.15829/1728-8800-2022-3235. Драпкина О.М., Шишкова В.Н., Котова М.Б. Психоэмоциональные факторы риска хронических неинфекционных заболеваний в амбулаторной практике. Методические рекомендации для терапевтов. Кардио васкулярная терапия и профилактика. 2022;21(10):3438. https://doi.org/10.15829/1728-8800-2022-3438. Шишкова В.Н., Драницына Б.Г., Драпкина О.М. Алгоритмы ведения пациентов с тревогой в практике терапевта. Кардиоваскулярная терапия и профилактика. 2023;22(2):3526. https://doi.org/10.15829/1728-88002023-3526. Tong A., Wang X., Li F., Xu F., Li Q., Zhang F. Risk of depressive symptoms associated with impaired glucose metabolism, newly diagnosed diabetes, and previously diagnosed diabetes: a meta-analysis of prospective cohort studies. Acta Diabetol. 2016;53(4):589–598. https://doi.org/10.1007/s00592-016-0845-1. Palmer S., Vecchio M., Craig J.C., Tonelli M., Johnson D.W., Nicolucci A. et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–191. https://doi.org/10.1038/ki.2013.77. Xiao T., Qiu H., Chen Y., Zhou X., Wu K., Ruan X., Wang N., Fu C. Prevalence of anxiety and depression symptoms and their associated factors in mild COPD patients from community settings, Shanghai, China: a cross-sectional study. BMC Psychiatry. 2018;18(1):89. https://doi.org/10.1186/s12888-018-1671-5. Krebber A.M., Buffart L.M., Kleijn G., Riepma I.C., de Bree R., Leemans C.R. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014;23(2):121–130. https://doi.org/10.1002/pon.3409. Read J.R., Sharpe L., Modini M., Dear B.F. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017;221:36–46. https://doi.org/10.1016/j.jad.2017.06.009. Ronaldson A., Arias de la Torre J., Prina M., Armstrong D., Das-Munshi J., Hatch S. et al. Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank. Lancet Reg Health Eur. 2021;8:100149. https://doi.org/10.1016/j.lanepe.2021.100149. Long J., Ouyang Y., Duan H., Xiang Z., Ma H., Ju M., Sun D. Multiple Factor Analysis of Depression and/or Anxiety in Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020;15:1449–1464. https://doi.org/10.2147/COPD.S245842. Wen-Tao D., Xue-Xiu C., Zun-Jiang C., Wei C., Cheng-Feng P., Xing-Ken F. The Relationship Between Hospitalization Frequency of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Anxiety and Depression. Front Genet. 2022;13:817727. https://doi.org/10.3389/fgene.2022.817727. Volpato E., Toniolo S., Pagnini F., Banfi P. The Relationship Between Anxiety, Depression and Treatment Adherence in Chronic Obstructive Pulmonary Disease: A Systematic Review. Int J Chron Obstruct Pulmon Dis. 2021;16:2001–2021. https://doi.org/10.2147/COPD.S313841. Ställberg B., Janson C., Larsson K., Johansson G., Kostikas K., Gruenberger J.B. et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. https://doi.org/10.1038/s41533-018-0101-y. Zareifopoulos N., Bellou A., Spiropoulou A., Spiropoulos K. Prevalence, Contribution to Disease Burden and Management of Comorbid Depression and Anxiety in Chronic Obstructive Pulmonary Disease: A Narrative Review. COPD. 2019;16(5-6):406–417. https://doi.org/10.1080/15412555.2019.1679102. Peyrot M., Rubin R.R., Lauritzen T., Snoek F.J., Matthews D.R., Skovlund S.E. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379–1385. https://doi.org/10.1111/j.1464-5491.2005.01644.x. Perrin N.E., Davies M.J., Robertson N., Snoek F.J., Khunti K. The prevalence of diabetes-specific emotional distress in people with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34(11):1508–1520. https://doi.org/10.1111/dme.13448. Mezuk B., Eaton W.W., Albrecht S., Golden S.H. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383–2390. https://doi.org/10.2337/dc08-0985. Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with Type 1 diabetes: systematic literature review. Diabet Med. 2006;23(4):445–448. https://doi.org/10.1111/j.1464-5491.2006.01814.x. Huang C.J., Hsieh H.M., Tu H.P., Jiang H.J., Wang P.W., Lin C.H. Generalized anxiety disorder in type 2 diabetes mellitus: prevalence and clinical characteristics. Braz J Psychiatry. 2020;42(6):621–629. https://doi.org/10.1590/1516-4446-2019-0605. Deschênes S.S., Burns R.J., Schmitz N. Associations between diabetes, major depressive disorder and generalized anxiety disorder comorbidity, and disability: findings from the 2012 Canadian Community Health Survey – Mental Health (CCHS-MH). J Psychosom Res. 2015;78(2):137–142. https://doi.org/10.1016/j.jpsychores.2014.11.023. Ásbjörnsdóttir B., Vestgaard M., Do N.C., Ringholm L., Andersen L.L.T., Jensen D.M. et al. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control. Diabet Med. 2021;38(3):e14506. https://doi.org/10.1111/dme.14506. Van der Feltz-Cornelis C., Allen S.F., Holt R.I.G., Roberts R., Nouwen A., Sartorius N. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: Systematic review and meta-analysis. Brain Behav. 2021;11(2):e01981. https://doi.org/10.1002/brb3.1981. Winkley K., Upsher R., Stahl D., Pollard D., Kasera A., Brennan A. et al. Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review. Health Technol Assess. 2020;24(28):1–232. https://doi.org/10.3310/hta24280. Stasiak C.E., Bazan K.S., Kuss R.S., Schuinski A.F., Baroni G. Prevalence of anxiety and depression and its comorbidities in patients with chronic kidney disease on hemodialysis and peritoneal dialysis. J Bras Nefrol. 2014;36(3):325–331. https://doi.org/10.5935/0101-2800.20140047. Nagler E.V., Webster A.C., Vanholder R., Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736–3745. https://doi.org/10.1093/ndt/gfs295. Chilcot J., Farrington K. The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease. J Am Soc Nephrol. 2019;30(7):1339–1340. https://doi.org/10.1681/ASN.2019030308. Wasteson E. Mood disorders in patients with cancer. Lancet Oncol. 2011;12(2):114–115. https://doi.org/10.1016/S1470-2045(11)70007-9. Wang Y.H., Li J.Q., Shi J.F., Que J.Y., Liu J.J., Lappin J.M. et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487–1499. https://doi.org/10.1038/s41380-019-0595-x. Celano C.M., Millstein R.A., Bedoya C.A., Healy B.C., Roest A.M., Huffman J.C. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105–1115. https://doi.org/10.1016/j.ahj.2015.09.013. Шишкова В.Н., Устарбекова Д.Б., Шишков В.А., Имамгаязова К.Э., Капустина Л.А. Психоэмоциональные нарушения у пациентов с хронической сердечной недостаточностью. Терапия. 2022;(1):44–49. https://doi.org/10.18565/therapy.2022.1.44-49. Шишкова В.Н. Простые и эффективные решения в коррекции тревоги и стресса. Медицинский совет. 2023;(3):161–167. https://doi.org/10.21518/ms2023-023. Vaccarino V., Badimon L., Bremner J.D, Cenko E., Cubedo J., Dorobantu M. et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J. 2020;41(17):1687–1696. https://doi.org/10.1093/eurheartj/ehy913. Daskalopoulou M., George J., Walters K., Osborn D.P., Batty G.D., Stogiannis D. et al. Depression as a Risk Factor for the Initial Presentation of Twelve Cardiac, Cerebrovascular, and Peripheral Arterial Diseases: Data Linkage Study of 1.9 Million Women and Men. PLoS ONE. 2016;11(4):e0153838. https://doi.org/10.1371/journal.pone.0153838. Peters A., McEwen B.S. Stress habituation, body shape and cardiovascular mortality. Neurosci Biobehav Rev. 2015;56:139–150. https://doi.org/10.1016/j.neubiorev.2015.07.001. Albus C., Waller C., Fritzsche K., Gunold H., Haass M., Hamann B. et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175–1196. https://doi.org/10.1007/s00392-019-01488-w. Smyth A., O’Donnell M., Lamelas P., Teo K., Rangarajan S., Yusuf S. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. Circulation. 2016;134(15):1059–1067. https://doi.org/10.1161/CIRCULATIONAHA.116.023142. Евстифеева С.Е., Шальнова С.А., Макарова Ю.К., Яровая Е.Б., Баланова Ю.А., Имаева А.Э. и др. Ассоциируется ли уровень тревоги и депрессии в популяции со смертностью населения? По данным исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2021;20(5):3009. https://doi.org/10.15829/1728-8800-2021-3009. Moise N., Khodneva Y., Jannat-Khah D.P., Richman J., Davidson K.W., Kronish I.M. et al. Observational study of the differential impact of time-varying depressive symptoms on all-cause and cause-specific mortality by health status in community-dwelling adults: the REGARDS study. BMJ Open. 2018;8(1):e017385. https://doi.org/10.1136/bmjopen-2017-017385. Ye S., Muntner P., Shimbo D., Judd S.E., Richman J., Davidson K.W., Safford M.M. Behavioral mechanisms, elevated depressive symptoms, and the risk for myocardial infarction or death in individuals with coronary heart disease: the REGARDS (Reason for Geographic and Racial Differences in Stroke) study. J Am Coll Cardiol. 2013;61(6):622–630. https://doi.org/10.1016/j.jacc.2012.09.058. Tully P.J., Cosh S.M., Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 2014;77(6):439–448. https://doi.org/10.1016/j.jpsychores.2014.10.001. Thompson D.R., Ski C.F. Psychosocial interventions in cardiovascular disease – what are they? Eur J Prev Cardiol. 2013;20(6):916–917. https://doi.org/10.1177/2047487313494031. Pizzi C., Rutjes A.W., Costa G.M., Fontana F., Mezzetti A., Manzoli L. Metaanalysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972–979. https://doi.org/10.1016/j.amjcard.2010.11.017. He W., Zhou Y., Ma J., Wei B., Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2020;25(6):919–926. https://doi.org/10.1007/s10741-019-09850-w. Honkola J., Hookana E., Malinen S., Kaikkonen K.S., Junttila M.J., Isohanni M. et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J. 2012;33(6):745–751. https://doi.org/10.1093/eurheartj/ehr368. Шишкова В.Н. Стратегия ведения и профилактики психоэмоциональных нарушений в практике терапевта. Медицинский совет. 2023;(6):76–82. https://doi.org/10.21518/ms2023-077. Стаценко М.Е., Говоруха О.А. Влияние Грандаксина на показатели качества жизни и темп реабилитации больных с сердечной недостаточностью, перенесших инфаркт миокарда. Лекарственный вестник. 2004;(2):23–28. Режим доступа: http://attic.volgmed.ru/publishing/lv/s/2004/2/lv-2004-2–023.pdf. Кулешова Э.В. Применение тофизопама (грандаксина) для лечения больных ишемической болезнью сердца. Клиническая фармакология и терапия. 2000;9(5):53–55. Режим доступа: https://medi.ru/info/8089/. Левин О.С. Применение буспирона в клинической практике. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(4):83–87. https://doi.org/10.17116/jnevro20151154183-87. Authors publishing their articles in this journal shall agree to the following:Authors reserve the copyright to the work and grant the journal a license to publish the work for the first time Creative Commons Attribution License (CC BY- NC-ND), which allows other persons to distribute this work with the obligatory preservation of references to the authors of the original work and the original publication in this journal.Authors reserve the right to conclude separate contractual arrangements regarding the non-exclusive distribution of the work version in the form published here (for example, posting it in the institute’s repository, publication in a book), with reference to its original publication in this journal.Authors have the right to post work on the Internet (for example, in the institute’s repository or personal website) before and during the process of considering it by this journal, as this can result in a productive discussion and more references to this work. Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License (CC BY- NC-ND), которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию.Авторы имеют право размещать работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу. (См. The Effect of Open Access). Meditsinskiy sovet = Medical Council; № 13 (2023); 256-262 Медицинский Совет; № 13 (2023); 256-262 2658-5790 2079-701X буспирон depression anxiety disorders chronic non-communicable diseases comorbidity tofisopam buspirone депрессия тревожные расстройства хронические неинфекционные заболевания коморбидность тофизопам info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 2023 ftjmedsovet https://doi.org/10.21518/ms2023-23010.1016/s01406736(18)32279-710.15829/1728-8800-2022-323510.15829/1728-8800-2022-343810.15829/1728-88002023-352610.1007/s00592-016-0845-110.1038/ki.2013.7710.1186/s12888-018-1671-510.1002/pon.340910.1016/j.jad.2017.06.009 2023-08-29T17:13:08Z Psycho-emotional disorders such as depression and anxiety disorders are important modifiable risk factors for the development and complicated course of many common chronic non-communicable diseases. A particular feature of such comorbidity is the significant impact of psycho-emotional disorders on the motivation and adherence of patients to a healthy lifestyle and various therapy options, which increases the risks of complications and, as a consequence of this, the healthcare expenditures. The topicality of the issues of screening and management of psycho-emotional disorders in the general practitioner practice is caused, on the one hand, by high rate of these disorders in patients with chronic non-communicable diseases, deterioration in quality of life and an increase in adverse outcomes, and on the other hand, inadequate awareness of the possibilities to manage the psycho-emotional state of patients with comorbidities. The therapy for psycho-emotional disorders includes both drug and non-drug methods, however, the effectiveness of such therapy in relation to the clinical course and prognosis in patients with different comorbidities is not the same. This review presents the most common comorbidities of psycho-emotional disorders and somatic diseases in therapeutic practice. A buspirone and tofisopam therapy for psycho-emotional disorders in patients with various comorbidities was discussed. The efficacy and safety of tofisopam and buspirone have been studied in numerous studies in patients with chronic diseases and a wide range of anxiety disorders, including a long-term administration. Психоэмоциональные нарушения, такие как депрессия и тревожные расстройства, являются важными модифицируемыми факторами риска развития и осложненного течения многих распространенных хронических неинфекционных заболеваний. Особенностью данной коморбидности является значимое влияние психоэмоциональных расстройств на мотивацию и приверженность пациентов к здоровому образу жизни и различным вариантам терапии, увеличивая риски ... Article in Journal/Newspaper Arctic Medical Council (E-Journal)

Similar Items